<code id='F5C5F6E42F'></code><style id='F5C5F6E42F'></style>
    • <acronym id='F5C5F6E42F'></acronym>
      <center id='F5C5F6E42F'><center id='F5C5F6E42F'><tfoot id='F5C5F6E42F'></tfoot></center><abbr id='F5C5F6E42F'><dir id='F5C5F6E42F'><tfoot id='F5C5F6E42F'></tfoot><noframes id='F5C5F6E42F'>

    • <optgroup id='F5C5F6E42F'><strike id='F5C5F6E42F'><sup id='F5C5F6E42F'></sup></strike><code id='F5C5F6E42F'></code></optgroup>
        1. <b id='F5C5F6E42F'><label id='F5C5F6E42F'><select id='F5C5F6E42F'><dt id='F5C5F6E42F'><span id='F5C5F6E42F'></span></dt></select></label></b><u id='F5C5F6E42F'></u>
          <i id='F5C5F6E42F'><strike id='F5C5F6E42F'><tt id='F5C5F6E42F'><pre id='F5C5F6E42F'></pre></tt></strike></i>

          entertainment

          entertainment

          author:Wikipedia    Page View:7
          3d heart myocarditis
          Adobe

          A drug developed by the biotech firm BridgeBio to treat an increasingly common heart condition succeeded in its main goal in a clinical trial, the company said Monday, and also pointed to potential reductions in hospitalization and death.

          The results may give the medicine, acoramidis, a path to the market after a failure that led its maker’s stock to plunge in December 2021.

          advertisement

          In the time since the initial failure, a rival Pfizer drug has become even more entrenched and another medicine, from Alnylam Pharmaceuticals, has had a successful clinical readout in the heart disease, known as ATTR-CM, in which a defective protein leads clumps to build up in the heart.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Anesthesiologist group: stop taking Ozempic before surgery
          Anesthesiologist group: stop taking Ozempic before surgery

          EspeciallyinthefirstweeksoftakingdrugslikeOzempic,foodstayslongerinthestomach—aprobleminsurgeries.Ad

          read more
          Snackable artificial intelligence, expert AI, and the pharma industry
          Snackable artificial intelligence, expert AI, and the pharma industry

          AdobeWhileit’swidelyacceptedthatthepharmaindustryisinnovativeinR&D,itisalsotruethatitcanbeslowat

          read more
          DIEP, the 'gold standard' of breast reconstruction, is under threat
          DIEP, the 'gold standard' of breast reconstruction, is under threat

          AdobeIn1983,Iflewhomefromcollegetobewithmymotherasshewokeupfromamastectomy.Sheoptedoutofbreastrecons

          read more

          What drug price negotiations mean for Medicare Part D

          AdobeAftertherecentannouncementofthefirst10drugsselectedforMedicarepricenegotiation,muchhasbeendiscu